Arbutus Biopharma Corp (NAS:ABUS)
$ 3.34 -0.29 (-7.99%) Market Cap: 630.32 Mil Enterprise Value: 557.49 Mil PE Ratio: 0 PB Ratio: 5.22 GF Score: 60/100

Q4 2022 Arbutus Biopharma Corp Earnings Call Transcript

Mar 02, 2023 / 01:45PM GMT
Release Date Price: $2.81
Operator

Good day, and thank you for standing by. Welcome to the Arbutus Biopharma Corporation Fourth Quarter and Year-End 2022 Financial Results and Corporate Update Conference Call. (Operator Instructions) Please be advised today's conference is being recorded. I would now like to hand the conference over to your speaker today, Lisa Caperelli. Please go ahead.

Lisa M. Caperelli
Arbutus Biopharma Corporation - VP of IR

Thank you, Kevin. Good morning, everyone, and thank you for joining Arbutus' Fourth Quarter and Year-end 2022 Financial Results and Corporate Update Call. Joining me today from the Arbutus executive team are Bill Collier, President and Chief Executive Officer; David Hastings, Chief Financial Officer; and Dr. Mike Sofia, Chief Scientific Officer.

Bill will begin with a corporate update, followed by Dr. Sofia who will provide an overview of our newly nominated coronavirus compound AB-343. Dave Hastings will then provide a review of the company's fourth quarter and year-end 2022 financial results. After our prepared remarks, we will open the call

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot